We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 56

The rise of parallel proceedings in health care fraud investigations: how to tell when you’re a target
  • Jones Day
  • USA
  • April 11 2014

When Dewey & LeBoeuf lawyer Zachary Warren was indicted for fraud recently, his surprised reaction made headlines.1 Warren, The New York Times


SEC alleges securities fraud by biopharmaceutical company and executives
  • Jones Day
  • USA
  • September 6 2011

On August 1, 2011, the SEC brought suit against Immunosyn Corporation, Argyll Biotechnologies LLC, and four executives, alleging that they had committed securities fraud related to misleading statements regarding the status of regulatory approvals during 200610


Recent developments in FCA cases: filings, motions, settlements, and trial verdicts
  • Jones Day
  • USA
  • April 21 2011

Recent notable False Claims Act (FCA) cases involving participants in the health care industry include the following


Former CEO sentenced to one month imprisonment and ordered to pay $1.9 million
  • Jones Day
  • USA
  • April 21 2011

On March 10, 2011, the former CEO of K-V Pharmaceutical, Marc Hermelin, was sentenced to 30 days in prison after pleading guilty to two federal charges of misbranding drugs


Purdue executives appeal order upholding exclusion
  • Jones Day
  • USA
  • April 21 2011

On January 31, 2011, three former Purdue executives filed an appeal to challenge Judge Ellen Segal Huvelle's (D.D.C.) order upholding the HHS Secretary's decision to exclude them from participation in federal health care programs


Former in-house counsel with pharmaceutical company reindicted
  • Jones Day
  • USA
  • April 21 2011

On April 13, 2011, a federal grand jury in Maryland returned an indictment charging Lauren Stevens, formerly a vice president and associate general counsel for GlaxoSmithKline (GSK), with obstruction of justice and making false statements to the Food and Drug Administration (FDA) in connection with an investigation into allegations that the drug Wellbutrin had been marketed for unapproved uses


U.S. Supreme Court rules that a drug’s adverse event reports may be material to investors even though not "statistically significant"
  • Jones Day
  • USA
  • March 28 2011

On March 22, 2011, the U.S. Supreme Court issued its long-awaited opinion in Matrixx Initiatives, Inc. v. Siracusano (No. 09-1156


Federal agencies expand outreach and ramp up resources for health care enforcement
  • Jones Day
  • USA
  • April 21 2011

HHS and the Department of Justice (DOJ) have initiated several programs to enhance awareness of health care compliance requirements and enforcement efforts and to significantly increase the resources devoted to detecting fraud and abuse in the health care industry


Former CEO sentenced to home detention and probation in off-label case; motions for new trial are denied
  • Jones Day
  • USA
  • April 21 2011

On April 13, 2011, the former CEO of InterMune, W. Scott Harkonen, was sentenced to three years of probation, six months of home detention (stayed pending appeal), and 200 hours of community service, and ordered to pay a $20,000 fine, based on his 2009 federal wire fraud conviction for creating and distributing a false and misleading press release related to an unapproved use of the drug Actimmune


Bill to address integrity and accountability is introduced
  • Jones Day
  • USA
  • April 21 2011

On March 2, 2011, Senator Chuck Grassley (R-Iowa) introduced a bill (S.454) containing several measures designed to address health care fraud (Strengthening Program Integrity and Accountability in Health Care Act of 2011